Efectividad y seguridad de los fármacos biológicos y las moléculas pequeñas en la hidradenitis supurativa: experiencia en un centro terciario y propuesta de un algoritmo terapéutico

• Miguel Mansilla-Polo ^[2] ; Begoña Escutia-Muñoz ^[2] ; David Hervás-Marín ^[1] ; Blanca de Unamuno-Bustos ^[2] ; Carlos Abril-Pérez ^[2] ; Rafael Botella-Estrada ^[3]
  1. [1] Universidad Politécnica de Valencia

     Universidad Politécnica de Valencia

     Valencia, España

     
  2. [2] Departamento de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, España. Instituto de Investigación Sanitaria (IIS) La Fe, Valencia, España
  3. [3] Departamento de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, España. Instituto de Investigación Sanitaria (IIS) La Fe, Valencia, España. Facultad de Medicina, Universidad de Valencia, Valencia, España

  Mostrar afiliaciones +
• Localización: Piel: Formación continua en dermatología, ISSN 0213-9251, Vol. 39, Nº. 6 (Junio-Julio), 2024, págs. 317-330
• Idioma: español
• DOI: 10.1016/j.piel.2024.02.001
• Títulos paralelos:
  • Effectiveness and safety of biologic and small molecule drugs in hidradenitis suppurativa: A tertiary center experience and a therapeutic algorithm proposal
• Enlaces
  • Texto Completo Ejemplar
• Resumen
  • español

    Introducción la hidradenitis supurativa una enfermedad inflamatoria cutánea en ocasiones devastadora. Actualmente, adalimumab es el único medicamento biológico o molécula pequeña aprobado en su tratamiento.

    Objetivos evaluar la eficacia y seguridad de los medicamentos biológicos y las moléculas pequeñas diferentes a adalimumab, con el objetivo final de proponer un algoritmo terapéutico estandarizado.

    Métodos se realizó un estudio retrospectivo con todos los medicamentos biológicos o de molécula pequeña diferentes a adalimumab en un hospital terciario. Se registraron mediciones objetivas y subjetivas mediante un análisis antes (previo a la introducción del medicamento) vs. después (retirada del medicamento o tiempo de finalización del estudio).

    Resultados se encontraron tasas de respuesta mejores que adalimumab en la mayoría de los ítems de respuesta objetiva (Hurley, IHS4, HSSI, Sartorius modificado) y subjetiva (DLQI, dolor, picazón, relaciones sexuales, satisfacción terapéutica) en infliximab, seguido de ustekinumab, brodalumab y secukinumab.

  • English

    Introduction Hidradenitis suppurativa is an occasionally devastating inflammatory skin disease. Currently, adalimumab is the only approved biological or small molecule medication for its treatment.

    Objectives To evaluate the efficacy and safety of biological or small molecule drugs other than adalimumab, with the ultimate goal of proposing a standardized therapeutic algorithm.

    Methods A retrospective study was conducted with all biological or small molecule drugs other than adalimumab in a tertiary hospital. Objective and subjective measurements were recorded through an analysis before (prior to the introduction of the medication) vs. after (withdrawal of the medication or end of the study period).

    Results Better response rates than adalimumab were found in most of the objective response items (Hurley, IHS4, HSSI, modified Sartorius) and subjective response items (DLQI, pain, itching, sexual relationships, therapeutic satisfaction) with infliximab leading, followed by ustekinumab, brodalumab, and secukinumab.

• Referencias bibliográficas
  • Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology....
  • Chen WT, Chi CC. Association of hidradenitis suppurativa with inflammatory bowel disease. JAMA Dermatol. 2019;155(9): 1022. https://doi.org/10.1001/jamadermatol.2019.0891.
  • Dufour DN, Emtestam L, Jemec GB. Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgrad...
  • Jalenques I, Ciortianu L, Pereira B, et al. The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa:...
  • Yen CF, Huang Y, Chi C. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: a case series. Indian J Dermatol...
  • Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a populationbased study of Olmsted...
  • Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic...
  • van Straalen KR, Prens EP, Willemsen G, et al. Contribution of genetics to the susceptibility to hidradenitis suppurativa in a large, cross-sectional...
  • Merilahti JAM, Ojala VK, Knittle AM, et al. Genome-wide screen of gamma-secretase–mediated intramembrane cleavage of receptor tyrosine kinases....
  • Li A, Peng Y, Taiclet LM, et al. Analysis of hidradenitis suppurativa–linked mutations in four genes and the effects of PSEN1-P242LfsX11 on...
  • Giatrakos S, Huse K, Kanni T, et al. Haplotypes of IL-12Rβ1 impact on the clinical phenotype of hidradenitis suppurativa. Cytokine. 2013;62(2):297–301....
  • König A, Lehmann C, Rompel R, et al. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology. 1999;198(3):261–264....
  • Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity....
  • Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa,...
  • Kromann CB, Ibler KS, Kristiansen VB, et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta...
  • Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative crosssectional study of 3207 patients....
  • Margesson LJ, Danby FW. Hidradenitis suppurativa. Dermatol Clin. 2010;28(4):779–793. https://doi.org/10.1016/j.det.2010. 07.003.
  • de Winter K, van der Zee HH, Prens EP. Is mechanical stress an important pathogenic factor in hidradenitis suppurativa? Exp Dermatol. 2012;21(3):176–177....
  • Morgan WP, Leicester G. The role of depilation and deodorants in hidradenitis suppurativa. Arch Dermatol. 1982;118(2):101. https://doi.org/10.1001/archderm.1982.01650140033014.
  • Pedraz J, Daudén E. Manejo práctico de la hidrosadenitis supurativa [Practical management of hidradenitis suppurativa]. Actas Dermosifiliogr....
  • Zouboulis CC. 11th European Hidradenitis Suppurativa Foundation (EHSF) e.V. Conference - Innovating the HS future. Exp Dermatol. 2022;31(suppl...
  • Mendonça CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154(5):977–978....
  • Join-Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampinmoxifloxacin-metronidazole combination therapy in hidradenitis suppurativa....
  • Stellon AJ, Wakeling M. Hidradenitis suppurativa associated with use of oral contraceptives. BMJ. 1989;298(6665):28–29. https://doi.org/10.1136/bmj.298.6665.28.
  • Farrell AM, Randall VA, Vafaee T, et al. Finasteride as a therapy for hidradenitis suppurativa. Br J Dermatol. 1999;141(6): 1136–1152. https://doi.org/10.1046/j.1365-2133.1999.03224.x.
  • Bermudez NM, Hargis A, Yaghi M, et al. Hidradenitis suppurativa: surgery, lasers, and emerging techniques. Sur Technol Onl. 2023;22:42. https://doi.org/10.52198/23.sti.42. wh1659.
  • Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis...
  • Jemec GBE, Gottlieb A, Forman S, et al. Efficacy and safety of adalimumab in patients with moderate to severe hidradenitis suppurativa: Results...
  • Fletcher JM, Moran B, Petrasca A, et al. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201(2):121–134....
  • Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an...
  • Di Caprio R, Balato A, Caiazzo G, et al. IL-36 cytokines are increased in acne and hidradenitis suppurativa. Arch Dermatol Res. 2017;309(8):673–678....
  • Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4): 736–744. https://doi.org/10.1016/j.jaad.2016.12.005.
  • Frew JW, Marzano AV, Wolk K, et al. A systematic review of promoting therapeutic targets in hidradenitis suppurativa: a critical evaluation...
  • Öztürk GS, Ergun T, Peker Eyüboğlu İP, et al. Serum highsensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A...
  • Garbayo-Salmons P, Expósito V, Ribera M, et al. Hidradenitis suppurativa treated with apremilast: a case series. Actas Dermosifiliogr (Engl...
  • Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021;30(suppl...
  • Huang CH, Hsin Huang I, Tai CC, Chi CC. Biologics and small molecule inhibitors for treating hidradenitis suppurativa: a systematic review...
  • Hedeker D. Methods for multilevel ordinal data in prevention research. Prev Sci. 2014;16(7):997–1006. https://doi.org/10.1007/ s11121-014-0495-x.
  • Zouboulis CC, Tzellos T, Kyrgidis A, European Hidradenitis Suppurativa Foundation Investigator Group, et al. Development and validation of...
  • Chiricozzi A, Faleri S, Franceschini C, et al. AISI: a new disease severity assessment tool for hidradenitis suppurativa. Wounds. 2015;27(10):258–264.
  • Chernyshov P, Zouboulis C, Aragonés LT, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European...
  • Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434....
  • Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa:...
  • Zouboulis CC, Hansen H, Caposiena RD, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/ acne inversa. Dermatology....
  • Sánchez Martínez EM, Murray G, Alfageme Roldán F, et al. Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety...
  • Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149(5):1046–1049. https://doi.org/10.1111/j.1365-2133.2003.05663.x.
  • Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol Br J Dermatol. 2006;155(5):1105–1107....
  • Fardet L, Dupuy A, Kerob D, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients....
  • Lasocki A, Sinclair R, Foley P, et al. Hidradenitis suppurativa responding to treatment with infliximab. Australas J Dermatol. 2010;51(3):186–190....
  • Paradela S, Rodríguez-Lojo R, Fernández-Torres R, et al. Longterm efficacy of infliximab in hidradenitis suppurativa. J Dermatolog Treat....
  • Moriarty B, Jiyad Z, Creamer D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa. Br J Dermatol. 2014;170(4):986–987....
  • Shih T, Lee K, Grogan T, et al. Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis. Dermatol Ther. 2022;35(9):e15691....
  • Ghias MH, Johnston AD, Kutner AJ, et al. High-dose, highfrequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am...
  • Fernandez-Crehuet P, Haselgruber S, Padial-Gomez A, et al. Short-term effectiveness, safety, and potential predictors of response of secukinumab...
  • Navrazhina K, Frew JW, Grand D, et al. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa...
  • Scheel CH, Rached NA, Gambichler T. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin...
  • Arenbergerova M, Arenberger P, Marques E, et al. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after...
  • Frew JW, Navrazhina K, Sullivan-Whalen M, et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study....
  • Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad...
  • Eisen DB. Ustekinumab, another biologic with potential to help patients with hidradenitis suppurativa? Br J Dermatol. 2016;174(4):718–719....
  • Hollywood A, Murray G, Fleming S, et al. Ustekinumab in the management of hidradenitis suppurativa: a retrospective study. J Drugs Dermatol....
  • Sánchez-Martínez EM, García-Ruiz R, Moneva-Léniz LM, et al. Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa...
  • Scholl L, Hessam S, Garcovich S, et al. High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa. Eur J Dermatol. 2019;29(6):659–661....
  • Romaní J, Vilarrasa E, Martorell A, et al. Ustekinumab with intravenous infusion: results in hidradenitis suppurativa. Dermatology. 2020;236(1):21–24....
  • Kimball AB, Zouboulis CC, Sayed C, et al. Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety...
  • Glatt S, Jemec GBE, Forman S, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind,...
  • Cuenca-Barrales C, Montero-Vílchez T, Szepietowski JC, et al. Sexual impairment in patients with hidradenitis suppurativa: a systematic review....
  • Angeline K, van Hassel K, Janse I, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported...
  • Sisic M, Kirby JS, Boyal S, et al. Development of a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg. 2016; 21:152–155....
  • Pinard J, Vleugels RA, Joyce C, et al. Hidradenitis suppurativa burden of disease tool: pilot testing of a disease-specific quality of life...
  • Kirby J, Thorlacius L, Villumsen B, et al. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure...
  • Marrón S, Gómez-Barrera M, Aragonés LT, et al. Development and preliminary validation of the HSQoL-24 tool to assess quality of life in patients...
  • Chiricozzi A, Bettoli V, De Pità O, et al. HIDRAdisk: An innovative visual tool to assess the burden of hidradenitis suppurativa. J Eur Acad...
  • Tsai YC, Hung CY, Tsai TF. Efficacy and safety of biologics and small molecules for moderate-to-severe hidradenitis suppurativa: a systematic...